Last reviewed · How we verify

BI 1387446 200 μg

Boehringer Ingelheim · Phase 1 active Small molecule Quality 20/100

BI 1387446 200 μg is a Small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 development.

At a glance

Generic nameBI 1387446 200 μg
SponsorBoehringer Ingelheim
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BI 1387446 200 μg

What is BI 1387446 200 μg?

BI 1387446 200 μg is a Small molecule drug developed by Boehringer Ingelheim.

Who makes BI 1387446 200 μg?

BI 1387446 200 μg is developed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).

What development phase is BI 1387446 200 μg in?

BI 1387446 200 μg is in Phase 1.

What are the side effects of BI 1387446 200 μg?

Common side effects of BI 1387446 200 μg include Fatigue, Hypertension, Bradycardia, Cataract, Haemorrhoidal haemorrhage, Asthenia.

Related